193 related articles for article (PubMed ID: 36581878)
1. CYP46A1 activation by low-dose efavirenz enhances brain cholesterol metabolism in subjects with early Alzheimer's disease.
Lerner AJ; Arnold SE; Maxfield E; Koenig A; Toth ME; Fortin B; Mast N; Trombetta BA; Denker J; Pieper AA; Tatsuoka C; Raghupathy S; Pikuleva IA
Alzheimers Res Ther; 2022 Dec; 14(1):198. PubMed ID: 36581878
[TBL] [Abstract][Full Text] [Related]
2. Cholesterol-metabolizing enzyme cytochrome P450 46A1 as a pharmacologic target for Alzheimer's disease.
Mast N; Saadane A; Valencia-Olvera A; Constans J; Maxfield E; Arakawa H; Li Y; Landreth G; Pikuleva IA
Neuropharmacology; 2017 Sep; 123():465-476. PubMed ID: 28655608
[TBL] [Abstract][Full Text] [Related]
3. CYP46A1 Activation by Efavirenz Leads to Behavioral Improvement without Significant Changes in Amyloid Plaque Load in the Brain of 5XFAD Mice.
Petrov AM; Lam M; Mast N; Moon J; Li Y; Maxfield E; Pikuleva IA
Neurotherapeutics; 2019 Jul; 16(3):710-724. PubMed ID: 31062296
[TBL] [Abstract][Full Text] [Related]
4. CYP46A1-dependent and independent effects of efavirenz treatment.
Mast N; El-Darzi N; Petrov AM; Li Y; Pikuleva IA
Brain Commun; 2020; 2(2):fcaa180. PubMed ID: 33305262
[TBL] [Abstract][Full Text] [Related]
5. Cholesterol 24-Hydroxylation by CYP46A1: Benefits of Modulation for Brain Diseases.
Petrov AM; Pikuleva IA
Neurotherapeutics; 2019 Jul; 16(3):635-648. PubMed ID: 31001737
[TBL] [Abstract][Full Text] [Related]
6. In Vitro Activation of Cytochrome P450 46A1 (CYP46A1) by Efavirenz-Related Compounds.
Mast N; Verwilst P; Wilkey CJ; Guengerich FP; Pikuleva IA
J Med Chem; 2020 Jun; 63(12):6477-6488. PubMed ID: 31617715
[TBL] [Abstract][Full Text] [Related]
7. Unbiased insights into the multiplicity of the CYP46A1 brain effects in 5XFAD mice treated with low dose-efavirenz.
Mast N; Butts M; Pikuleva IA
J Lipid Res; 2024 Jun; 65(6):100555. PubMed ID: 38719151
[TBL] [Abstract][Full Text] [Related]
8. Increased Acetylcholine Levels and Other Brain Effects in 5XFAD Mice after Treatment with 8,14-Dihydroxy Metabolite of Efavirenz.
Mast N; Li Y; Pikuleva IA
Int J Mol Sci; 2022 Jul; 23(14):. PubMed ID: 35887013
[TBL] [Abstract][Full Text] [Related]
9. Brain Acetyl-CoA Production and Phosphorylation of Cytoskeletal Proteins Are Targets of CYP46A1 Activity Modulation and Altered Sterol Flux.
Mast N; Petrov AM; Prendergast E; Bederman I; Pikuleva IA
Neurotherapeutics; 2021 Jul; 18(3):2040-2060. PubMed ID: 34235635
[TBL] [Abstract][Full Text] [Related]
10. The key genes, phosphoproteins, processes, and pathways affected by efavirenz-activated CYP46A1 in the amyloid-decreasing paradigm of efavirenz treatment.
Petrov AM; Mast N; Li Y; Pikuleva IA
FASEB J; 2019 Aug; 33(8):8782-8798. PubMed ID: 31063705
[TBL] [Abstract][Full Text] [Related]
11. Brain sterol flux mediated by cytochrome P450 46A1 affects membrane properties and membrane-dependent processes.
Petrov AM; Mast N; Li Y; Denker J; Pikuleva IA
Brain Commun; 2020; 2(1):. PubMed ID: 32661514
[TBL] [Abstract][Full Text] [Related]
12. The potential of CYP46A1 as a novel therapeutic target for neurological disorders: An updated review of mechanisms.
Alavi MS; Karimi G; Ghanimi HA; Roohbakhsh A
Eur J Pharmacol; 2023 Jun; 949():175726. PubMed ID: 37062503
[TBL] [Abstract][Full Text] [Related]
13. Mapping of the Allosteric Site in Cholesterol Hydroxylase CYP46A1 for Efavirenz, a Drug That Stimulates Enzyme Activity.
Anderson KW; Mast N; Hudgens JW; Lin JB; Turko IV; Pikuleva IA
J Biol Chem; 2016 May; 291(22):11876-86. PubMed ID: 27056331
[TBL] [Abstract][Full Text] [Related]
14. New Therapeutic Targets for Brain Function and Disease.
van Lier JE
J Med Chem; 2020 Jun; 63(12):6474-6476. PubMed ID: 31845585
[TBL] [Abstract][Full Text] [Related]
15.
Mast N; Anderson KW; Johnson KM; Phan TTN; Guengerich FP; Pikuleva IA
J Biol Chem; 2017 Aug; 292(31):12934-12946. PubMed ID: 28642370
[TBL] [Abstract][Full Text] [Related]
16. The Hydroxylation Position Rather than Chirality Determines How Efavirenz Metabolites Activate Cytochrome P450 46A1 In Vitro.
Mast N; Fotinich A; Pikuleva IA
Drug Metab Dispos; 2022 Jul; 50(7):923-930. PubMed ID: 35489779
[TBL] [Abstract][Full Text] [Related]
17. 7,8-Dihydroxy Efavirenz Is Not as Effective in CYP46A1 Activation In Vivo as Efavirenz or Its 8,14-Dihydroxy Metabolite.
Mast N; Li Y; Pikuleva IA
Int J Mol Sci; 2024 Feb; 25(4):. PubMed ID: 38396919
[TBL] [Abstract][Full Text] [Related]
18. Pharmacologic stimulation of cytochrome P450 46A1 and cerebral cholesterol turnover in mice.
Mast N; Li Y; Linger M; Clark M; Wiseman J; Pikuleva IA
J Biol Chem; 2014 Feb; 289(6):3529-38. PubMed ID: 24352658
[TBL] [Abstract][Full Text] [Related]
19. The normalizing effects of the CYP46A1 activator efavirenz on retinal sterol levels and risk factors for glaucoma in Apoj
El-Darzi N; Mast N; Li Y; Dailey B; Kang M; Rhee DJ; Pikuleva IA
Cell Mol Life Sci; 2023 Jul; 80(7):194. PubMed ID: 37392222
[TBL] [Abstract][Full Text] [Related]
20. Therapeutic implications of altered cholesterol homeostasis mediated by loss of CYP46A1 in human glioblastoma.
Han M; Wang S; Yang N; Wang X; Zhao W; Saed HS; Daubon T; Huang B; Chen A; Li G; Miletic H; Thorsen F; Bjerkvig R; Li X; Wang J
EMBO Mol Med; 2020 Jan; 12(1):e10924. PubMed ID: 31777202
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
